Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Other Accumulated Expenses (2020 - 2025)

Historic Other Accumulated Expenses for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $4.7 million.

  • Apellis Pharmaceuticals' Other Accumulated Expenses fell 7821.9% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.7 million, marking a year-over-year decrease of 7821.9%. This contributed to the annual value of $3.0 million for FY2024, which is 7556.29% down from last year.
  • Apellis Pharmaceuticals' Other Accumulated Expenses amounted to $4.7 million in Q3 2025, which was down 7821.9% from $5.5 million recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Other Accumulated Expenses ranged from a high of $30.8 million in Q3 2023 and a low of $3.0 million during Q4 2024
  • Its 5-year average for Other Accumulated Expenses is $15.9 million, with a median of $14.1 million in 2021.
  • As far as peak fluctuations go, Apellis Pharmaceuticals' Other Accumulated Expenses skyrocketed by 25639.82% in 2021, and later plummeted by 7821.9% in 2025.
  • Apellis Pharmaceuticals' Other Accumulated Expenses (Quarter) stood at $12.8 million in 2021, then increased by 7.88% to $13.8 million in 2022, then fell by 11.94% to $12.2 million in 2023, then crashed by 75.56% to $3.0 million in 2024, then surged by 56.76% to $4.7 million in 2025.
  • Its Other Accumulated Expenses stands at $4.7 million for Q3 2025, versus $5.5 million for Q2 2025 and $3.8 million for Q1 2025.